Author:
Fang Luo,Sun Xiaojiang,Song Yu,Zhang Yiwen,Li Fanzhu,Xu Yaping,Ma Shenglin,Lin Nengming
Funder
Zhejiang Cancer Hospital Program for the Cultivation of 1022 Talents
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference30 articles.
1. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’Yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA, Brain Tumor Epidemiol C (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer Am Cancer Soc 113(7):1953–1968. doi: 10.1002/cncr.23741
2. Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126
3. Fortin D (2004) The blood-brain barrier should not be underestimated in neuro-oncology. Rev Neurol 160(5):523–532. doi: 10.1016/s0035-3787(04)70981-9
4. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K, Iizasa T (2013) Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82(2):282–287. doi: 10.1016/j.lungcan.2013.08.016
5. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Engl J Med 364(10):947–955. doi: 10.1056/NEJMct0807960
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献